DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Bruix J, Qin S, Merle P. , et al; RESORCE Investigators.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet 2017;
389 (10064): 56-66
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.